Nutriband Inc. (NTRB): Price and Financial Metrics


Nutriband Inc. (NTRB): $4.83

-0.18 (-3.59%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NTRB Stock Price Chart Interactive Chart >

Price chart for NTRB

NTRB Price/Volume Stats

Current price $4.83 52-week high $15.00
Prev. close $5.01 52-week low $2.81
Day low $4.67 Volume 14,467
Day high $4.94 Avg. volume 296,645
50-day MA $4.44 Dividend yield N/A
200-day MA $4.85 Market Cap 37.78M

Nutriband Inc. (NTRB) Company Bio


Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida


NTRB Latest News Stream


Event/Time News Detail
Loading, please wait...

NTRB Latest Social Stream


Loading social stream, please wait...

View Full NTRB Social Stream

Latest NTRB News From Around the Web

Below are the latest news stories about NutriBand Inc that investors may wish to consider to help them evaluate NTRB as an investment opportunity.

NTRB: Hitting Milestones on Path toward Regulatory Approval & Commercialization

By M. Marin NTRB:NASDAQ READ THE FULL NTRB RESEARCH REPORT Laying the groundwork to move forward Nutriband Inc. (NTRB:NASDAQ), an emerging a biopharma and medical device company that is developing a portfolio of transdermal pharmaceutical products, has hit several milestones to move AVERSA Fentanyl, a Fentanyl transdermal patch that leverages its AVERSA™ technology, towards regulatory approval

Yahoo | February 22, 2022

Nutriband Inc.'s Patent, 'Abuse and Misuse Deterrent Transdermal System’ Published by the United States Patent and Trademark Office Following Recent Issuance Notice

ORLANDO, FL / ACCESSWIRE / February 16, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the United States Patent and Trademark Office (USPTO) has published its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the Company's lead technology AVERSA™.

Yahoo | February 16, 2022

Nutriband Inc. To Participate in The Benzinga All Access Event on February 4

ORLANDO, FL / ACCESSWIRE / February 4, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) will be participating in the Benzinga ALL ACCESS, which will take place on February 4.

Yahoo | February 4, 2022

Nutriband Issued Full US Patent for Its Aversa(TM) Abuse Deterrent Transdermal Platform by United States Patent and Trademark Office

ORLANDO, FL / ACCESSWIRE / January 28, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced the receipt of an Issue Notification from the United States Patent and Trademark Office (USPTO) for its United States patent entitled, "Abuse and Misuse Deterrent Transdermal System," that protects its AVERSA™ transdermal abuse deterrent technology.

Yahoo | January 28, 2022

Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / January 18, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced an expanded product development pipeline for its proprietary AVERSA™ abuse deterrent transdermal technology.

Yahoo | January 18, 2022

Read More 'NTRB' Stories Here

NTRB Price Returns

1-mo 11.55%
3-mo 20.75%
6-mo -20.17%
1-year N/A
3-year N/A
5-year N/A
YTD -52.08%
2021 -32.80%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4487 seconds.